12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AYX1: Phase I data

A dose-escalation Phase I trial in 30 healthy volunteers showed that all 5 doses of AYX1 were well tolerated, with no serious adverse events...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >